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The most frequently mutated protein in human cancer is p53, a
transcription factor (TF) that regulates myriad genes instrumental
in diverse cellular outcomes including growth arrest and cell
death. Cell context-dependent p53 modulation is critical for this
life-or-death balance, yet remains incompletely understood. Here
we identify sequence signatures enriched in genomic p53-binding
sites modulated by the transcription cofactor iASPP. Moreover, our
p53–iASPP crystal structure reveals that iASPP displaces the p53
L1 loop—which mediates sequence-specific interactions with the
signature-corresponding base—without perturbing other DNA-
recognizing modules of the p53 DNA-binding domain. A TF com-
monly uses multiple structural modules to recognize its cognate
DNA, and thus this mechanism of a cofactor fine-tuning TF–DNA
interactions through targeting a particular module is likely wide-
spread. Previously, all tumor suppressors and oncoproteins that
associate with the p53 DNA-binding domain—except the onco-
genic E6 from human papillomaviruses (HPVs)—structurally cluster
at the DNA-binding site of p53, complicating drug design. By con-
trast, iASPP inhibits p53 through a distinct surface overlapping the
E6 footprint, opening prospects for p53-targeting precision medi-
cine to improve cancer therapy.
p53 | iASPP | crystal structure | target selectivity | HPV E6
The recognition of specific DNA sequences by transcriptionfactors (TFs) is instrumental for decoding genomes (1, 2).
Beyond the intrinsic TF sequence preferences, TF–DNA inter-
actions are further regulated, in a sequence-specific fashion,
through mechanisms such as interplay between TFs (3) and
transcription cofactors that modify TFs (4, 5), DNA (6, 7), and
histones (8). Intriguingly, a category of transcription cofactors
does not appreciably bind DNA and lacks apparent enzymatic
activities. Instead, the transcription cofactors directly interact with
the DNA-binding domains (DBDs) of TFs and alter TF–DNA
binding, thereby endowing partner TFs with transcriptional target
gene selectivity (9, 10). Hitherto, the sequence and structural basis
for this mode of TF regulation remains poorly characterized.
The apparently 53-kDa tumor suppressor and TF p53 is the
most frequently mutated protein in human cancer (11, 12). As a
master TF for stress responses, p53 regulates a complex array of
genes that can determine diverse cellular outcomes such as
growth arrest or death (13–15). How p53 regulates discrete
subsets of target genes and why p53 induction leads to cell-cycle
arrest in some cell types and apoptosis in others are not com-
pletely understood (16).
A common landmark of virtually all p53 target genes is a
stretch of specific DNA sequence, termed a response element
(RE). These p53 REs share the consensus sequence motif con-
sisting of 2 half sites, each being a 10-base pair (bp) palindrome
5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ (Pu, purine; Py, pyrimidine),
occasionally separated by a short spacer (17, 18). The intrinsic
sequence specificity of p53 is principally determined by the
multiple DNA-binding modules integrated in its DBD. The p53
DBD has an immunoglobulin (Ig)-like β-sandwich scaffold that
presents the so-termed loop–sheet–helix (LSH) motif to fit
snugly in the major groove of a DNA double helix and the
L3 loop to contact the adjacent minor groove as well as the DNA
backbone (19), and a p53 tetramer recognizes the full RE (20).
Crystal structures of p53–DNA complexes show that, within the
LSH motif responsible for direct base recognition, R280 from the
H2 helix makes invariant contacts with the conserved guanine in
the REs, whereas K120 from the L1 loop interacts with the
neighboring purines (on the opposite strand) in a sequence-
dependent manner (19–25). Consistently, the L1 loop has been
associated with p53 target selectivity (26, 27). Notably, the
acetylation of K120 within L1 further contributes to p53 pro-
moter specificity (5, 28).
The ASPP (apoptosis stimulating protein of p53) family of
transcription cofactors represent well-recognized promoter-specific
regulators of p53 (14, 29), and exemplars to explore further
mechanisms of TF selectivity in general (9, 30). ASPP1 and
ASPP2 promote transcriptional activities of p53 specifically on
apoptotic genes such as BAX and TP53I3 (PIG3) (31), whereas
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iASPP is inhibitory (32). Classically, their carboxyl (C)-terminal
conserved regions, each comprising ankyrin repeats and a Src
homology 3 (SH3) domain, directly bind to p53 DBD (33–35),
and iASPP has been shown to interact additionally with p53
regions flanking its DBD (36, 37). Paradoxically, the cocrystal
structure of p53–53BP2 (C-terminal ASPP2) demonstrated that
p53-stimulating ASPP2 occupies the DNA-binding surface of
p53 (31, 34). The detailed mechanism for sequence-specific
regulation of p53 by the ASPP family remains obscure. In this
study, we focus on the inhibitory iASPP and used RNA se-
quencing (RNA-seq) combined with chromatin immunopre-
cipitation followed by sequencing (ChIP-seq) to investigate
genome-wide p53 binding and transcriptional activities regu-
lated by iASPP in the HCT 116 colorectal carcinoma cell line,
which harbors wild-type p53. This led to the identification of
sequence signatures enriched in iASPP-modulated p53 REs
and associated target genes. In pursuit of the structural basis of
this selective p53 regulation, we solved the crystal structure of a
p53–iASPP complex and found that iASPP segregates the L1
loop of p53, which specifies the sequence signatures, from other
DNA-binding modules. It does so without blocking the major
DNA-binding surface of p53, a unique feature among struc-
turally characterized p53-interacting proteins.
Results
Sequence Signatures Enriched in iASPP-Regulated p53 REs. To ex-
pand knowledge of iASPP-regulated p53 target gene selectivity
from a handful of tested promoters to the breadth of the human
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Fig. 1. Genomic analysis of gene regulation by iASPP reveals sequence signatures enriched in iASPP-regulated p53 REs. (A) Fragments per kilobase of transcript per
million mapped reads (FPKM) values from RNA-seq analysis of HCT 116 cells under each experimental condition (see color codes on figure) for PPP1R13L (iASPP), TP53
(p53),MDM2, and 2 control genes, TP53BP1 and TP53BP2 (ASPP2) that have not been described as p53 transcriptional targets yet encode p53-binding partners. Two
batches of RNA-seq data (n = 2) were used. Error bars denote standard deviations (SDs). (B) The number of DE genes (FDR < 0.05, fold change > 2) under each
condition compared to the control siRNA treatment found by RNA-seq (Left). Venn diagram analysis (Right) of the DE genes. (C) Gene set enrichment analysis of iASPP-
regulated genes in KEGG pathways (475 genes) (Top) and genes up-regulated following iASPP depletion by related TFs (194 genes) (Bottom). (D) Heat map showing
RNA-seq derived gene expression profiles from RNAi experiments (listed Left) for 145 p53-regulated and -bound targets identified in this study. FPKM values plus
1 were used for the logarithmic calculations of fold changes. See SI Appendix, Fig. S1B for the definition of the 145 genes. (E) ChIP-seq using a p53 antibody (FL-393)
identified 214 elevated p53-binding peaks (fold change > 2) in iASPP-depleted cells versus control siRNA and 1,328 p53-binding peaks (fold change > 2) induced by
Nutlin compared to the DMSO control. Sequence logos depicting nucleotide distributions of the 20-base pair consensus p53-binding site based on iASPP-regulated
(Top) or Nutlin-induced (Bottom) response elements (spacers between half sites removed) generated using WebLogo (http://weblogo.berkeley.edu/). Prominent
differences of nucleotide distributions at positions 9 and 12 (framed in dashed lines) were observed. C9: 152 out of 208 REs or 73.1% in iASPP-regulated compared to
738 out of 1,290 REs or 57.2% in Nutlin-induced; 1.28-fold, P = 1.30 × 10−5. G12: 152 REs or 73.1% in iASPP-regulated compared to 722 REs or 56.0% in Nutlin-induced;
1.31-fold, P = 2.38 × 10−6. Concurrent: 121 out of 208 REs or 58.2% in iASPP-regulated compared to 541 out of 1,290 REs or 41.9% in Nutlin-induced; 1.39-fold, P =
1.63 × 10−5. Fisher’s exact test was used for the statistical analysis. (F) Scatterplot showing the enrichment of each nucleotide of the consensus p53-bindingmotif on the
x axis (fold change) and the corresponding P value on the y axis (−log10 scale) found in iASPP-regulated relative to Nutlin-induced p53 ChIP peaks. The fold changes
and P values were calculated using 2-tailed Fisher’s exact test. The horizontal dashed line represents the Bonferroni-corrected P value of 0.05.
Chen et al. PNAS | August 27, 2019 | vol. 116 | no. 35 | 17471
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genome, we initially attempted to generate iASPP-ablated de-
rivatives of wild-type p53-expressing cell lines using CRISPR-
Cas9. Unfortunately we were unable to generate such cell lines,
presumably due to the inhibition of CRISPR-Cas9 gene editing
by hyperactive p53 signaling following iASPP deletion (32, 38, 39).
Instead, by RNA interference (RNAi) we transiently depleted
iASPP (PPP1R13L) in the HCT 116 colorectal carcinoma cell
line, which expresses wild-type p53, and analyzed the effects on
gene expression with RNA-seq (Fig. 1A).
A total of 475 genes were differentially expressed (DE) (false
discovery rate [FDR] < 0.05, fold change > 2) in iASPP-depleted
cells compared to control cells, comprising 194 up-regulated and
281 down-regulated genes (Fig. 1B and SI Appendix, Fig. S1A).
Gene set enrichment analysis of these DE genes showed that
iASPP-regulated genes are enriched in the canonical p53 sig-
naling pathway (Kyoto Encyclopedia of Genes and Genomics
[KEGG] hsa04115, P = 3.5 × 10−13) and the transcripts up-
regulated by iASPP RNAi are enriched in transcriptional tar-
gets of p53 (P = 8.0 × 10−15) (Fig. 1C). As a positive control for
p53 activation, we treated HCT 116 cells with Nutlin, a small
molecule that stabilizes p53 by blocking MDM2-mediated
p53 degradation. In Nutlin-treated cells, 1,203 genes were dif-
ferentially expressed (Fig. 1 A and B and SI Appendix, Fig. S1B).
We observed significant albeit relatively weak up-regulation of
iASPP by Nutlin (FDR = 0.03, fold change = 1.7) (Fig. 1A),
consistent with iASPP being a p53 transcriptional target (40) and
contributing to p53 negative feedback. The concurrent depletion
of iASPP and p53 (TP53) resulted in a gene expression profile
more closely resembling that of p53 RNAi than iASPP depletion
(Fig. 1 A, B, and D). These results suggest that iASPP-mediated
gene regulation predominantly acts genetically upstream of the
TF p53, which has a low transcriptional activity under steady-
state conditions in cancer-derived HCT 116 cells.
To assess genome-wide p53 binding regulated by iASPP, we
performed ChIP-seq using an anti-p53 antibody in HCT 116 cells
treated with control or iASPP RNAi. A total of 214 p53-binding
sites showed elevated signals (fold change > 2) following iASPP
depletion (Fig. 1E). We used a previously reported position
weight matrix algorithm to predict p53 REs within the iASPP-
regulated p53 ChIP-seq peaks (41), and generated sequence
motifs to analyze nucleotide frequency (highest-scored RE per
peak; 208 REs from 214 peaks) (Fig. 1E). When the nucleotide
distributions of the iASPP-regulated motif were compared to the
consensus motif from the Nutlin-induced p53 REs (1,290 REs
from 1,328 peaks), we identified clear differences at 2 nucleotide
positions (Fig. 1 E and F). In iASPP-regulated REs, a cytosine
(C) was more prevalent at position 9 of a typical 20-bp p53
consensus motif while a guanine (G) was more dominant at
position 12 than in Nutlin-induced REs (Fig. 1E; C9: P = 1.30 ×
10−5; G12: P = 2.38 × 10−6; see figure legends for detailed sta-
tistics). The concurrent presence of C9 and G12 was enriched in
iASPP-regulated compared to Nutlin-induced REs (P = 1.63 ×
10−5). These findings suggest that the presence of C9 and/or
G12 in a typical 20-bp p53 motif likely represents the sequence
basis for iASPP-regulated p53 binding, which in turn underlies
gene regulation by iASPP.
Identification of iASPP-Regulated p53 Target Genes. To identify di-
rect, iASPP-regulated p53 target genes (iPTGs), we integrated
the RNA-seq and ChIP-seq results and found 13 iPTGs associ-
ated with 12 differential p53 ChIP-seq peaks following iASPP
depletion (Fig. 2 A–C and SI Appendix, Fig. S2). One of the
iASPP-regulated p53 ChIP peaks is shared by the overlapping
gene bodies of ACTA2 and FAS, and iASPP depletion promotes
the transcription of both genes (Fig. 2B). We examined the REs
within these 12 iASPP-regulated p53 ChIP-seq peaks and con-
firmed the concurrent presence of C9 and G12 in 9 out of the
12 p53-binding sites (Fig. 2C). We also extended our search in
representative p53 target genes and noted that this sequence
signature is present in p53 REs responsible for controlling key
apoptotic effectors BAX and PUMA (BBC3) in addition to FAS
and NOXA (PMAIP1) identified above (Fig. 2C). Conversely,
p53 REs for target mediators involved in some other functions,
such as DRAM1 (autophagy) and MDM2 (negative feedback)
(15), do not bear the full signature (Fig. 2C).
The 13 identified iPTGs are involved in diverse biological
functions (Fig. 2C), yet 9 out of 13 iPTGs have been linked to the
regulation of apoptosis, a hallmark of the ASPP family (42).
AEN, FAS, FHL2 (43, 44), and PMAIP1 promote p53-induced
apoptosis, whereas CDKN1A (p21), RAP2B (45), and TIGAR
have prosurvival and antiapoptotic properties (15). RPS27L (46)
and ZMAT3 (47) have been reported to promote or inhibit ap-
optosis in a context-dependent fashion. The remaining 4 iPTGs,
ACTA2 (48), HES2 (49), PARD6B (50), and SLC30A1 (51), are
implicated in other molecular processes including smooth muscle
contraction, transcriptional regulation, cell polarity, and zinc
transport, respectively.
Apart from CDKN1A, iASPP has not been studied in relation
to the transcriptional regulation of these iPTGs. Following iASPP
depletion, our RNA-seq and ChIP-seq data showed strong up-
regulation of transcription and enhanced p53 binding for TIGAR
(Fig. 2B), which modulates metabolism and lowers intracellular
reactive oxygen species (ROS) levels in response to mild metabolic
stress signals in favor of cell survival (52). We confirmed this result
in a luciferase reporter assay using p53-null cell lines H1299 and
Saos-2, in which iASPP inhibited p53-mediated transactivation of a
TIGAR response element (Fig. 2D). In contrast, iASPP depletion
resulted in only weak induction ofMDM2 (compared to substantial
induction in the presence of Nutlin), and MDM2 had similar p53
ChIP-seq signals in the presence or absence of iASPP (Fig. 2B),
which is consistent with a previous report (36). This suggests that
iASPP does not directly regulate MDM2-based p53 negative
feedback. Overall our combined genomic analysis reveals iASPP-
mediated, sequence-specific, differential regulation of p53 RE
binding and identified a set of previously unrecognized iPTGs.
Crystal Structure of a p53–iASPP Complex. We then set out to un-
derstand the structural basis for iASPP-mediated regulation of
p53–DNA interactions. The domain organization of a p53
monomer consists of an amino (N)-terminal transactivation do-
main (TAD), a proline-rich domain (PRD), a central, conserved
sequence-specific DBD, an oligomerization domain (OD) that
mediates tetramerization, and a carboxyl (C)-terminal regulatory
domain (CTD) (Fig. 3A and SI Appendix, Fig. S3A) (21). For
crystallographic analysis we used a p53 construct that includes
the PRD and DBD (residues 62 to 292) (Fig. 3A and SI Ap-
pendix, Fig. S3B) and a C-terminal iASPP construct (residues
625 to 828) (Fig. 3A and SI Appendix, Figs. S4 A and B and S5A).
These constructs enabled crystallization of the purified complex
(see Materials and Methods). X-ray diffraction data were col-
lected from microcrystals using a synchrotron light source and
processed to 4.25-Å resolution, allowing structure determination
of the complex by molecular replacement (Materials and Methods
and SI Appendix, Table S1).
Our final model includes p53 residues 91 to 291 with a co-
ordinated zinc2+ ion and iASPP residues 657 to 823; the crys-
tallographic asymmetric unit contains 1 such complex (Fig. 3B).
There was a lack of density for the proline-rich region of p53
(Fig. 3B and SI Appendix, Fig. S5 B and C), suggesting it is not
critical for the interaction between these truncated protein
constructs. The first ankyrin repeat of iASPP was not traceable in
the electron density (Fig. 3A and SI Appendix, Fig. S5D). The
structures of the individual components observed in the complex
are virtually identical to published structures of the p53 DBD
fold (a root-mean-square deviation [RMSD] of 0.28 Å for 194
Cα pairs compared to PDB entry 2XWR chain B) and iASPP (an
RMSD of 0.57 Å over 166 Cα pairs compared to PDB entry
2VGE), except for the L1 loop of p53 (residues 115 to 120 not
matched for the RMSD calculation) (Fig. 3C and SI Appendix,
Fig. S5 B–D), as discussed below.
The crystal lattice shows 3 intermolecular interfaces between
p53 and iASPP (SI Appendix, Fig. S6). Interface I has the largest
17472 | www.pnas.org/cgi/doi/10.1073/pnas.1909393116 Chen et al.
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(1,246.5 Å2) buried solvent-accessible surface area. Here, iASPP
almost exclusively uses a relatively flat surface of its ankyrin stack
(composed of residues exposed on the second α-helix of each
ankyrin repeat) to interact with the LSH motif of p53, prizing the
L1 loop away from its contacts with the S2 β-strand and the H2
α-helix (Fig. 3 B and C and SI Appendix, Fig. S6). iASPP F818,
situated in the C-terminal loop (tail) that is trapped between the
ankyrin repeats and the SH3 domain provides an auxiliary hy-
drophobic shield for the interface (Fig. 3 B and D). Interface I
contains both hydrophobic and hydrophilic elements, and the
surfaces are complementarily charged (Fig. 3D). Furthermore,
the interface area on p53 is composed of evolutionarily con-
served and varied patches, whereas on the iASPP ankyrin stack
the p53-binding surface is less conserved than the regions that
maintain the ankyrin-repeat fold (Fig. 3D). It is therefore pos-
sible that the modulation of the tumor suppressor p53 by iASPP
evolved late in vertebrates.
Interface II is the second largest (1,041.6 Å2) and is composed
predominantly of hydrophilic interactions. At this interface,
iASPP employs a different face of its ankyrin stack to engage
p53 at a surface that overlaps with its DNA-binding area (SI
Appendix, Fig. S6). Interface III is the smallest of the 3 (920.6 Å2)
where the SH3 domain of iASPP contacts the N-terminal loop of
p53 DBD, which wraps around the DBD, and the surrounding
p53 residues (SI Appendix, Fig. S6).
To investigate which p53–iASPP interface(s) observed in the
crystal lattice is required for binding, we performed an alanine
scan of p53 residues whose side chains are orientated to contact
iASPP exclusively at each interface and assayed the binding of
corresponding full-length p53 single-point mutants to our iASPP
crystallization construct. Where possible, residues with solvent-
exposed side chains on the apo structure of p53 DBD that do not
display apparent structural roles were chosen. Alanine substitu-
tions of interface I p53 residues H115 and R282 diminished and
enhanced p53–iASPP interactions, respectively, whereas mutations
of interface II p53 residues S121, R248, R280, and N288 to alanine
did not substantially affect the binding (Fig. 3E). Interface III
mutation p53K101A weakened p53–iASPP binding but p53R267A
retained the wild-type level of interaction (Fig. 3E). p53 residue
H115 is prominently exposed on the DBD surface of p53 in the
free or DNA-bound state, but is buried in the interface I-mediated
complex with iASPP (Fig. 3D). Our structural and mutational data
suggest that p53 H115 is a key residue mediating the p53–iASPP
interaction. R282 is 1 of the 6 main p53 mutational hotspots and is
the only hotspot that is not directly contacting DNA or involved in
structuring the DNA-binding L3 loop (Fig. 3B). R282 critically
maintains the structural integrity of the p53 LSH motif, and the
alanine substitution is predicted to disrupt the structural motif
and lead to a more flexible L1 loop. We attribute the increased
p53R282A–iASPP binding to the destabilization of the local
structure and creation of the cleft between the p53 L1 loop and
H2 helix for binding iASPP. In this binding assay, we further
analyzed charge-swapped p53 H115E, R282E, and K101E.
H115E and R282E (interface I) enhanced the respective phe-
notypes observed with the alanine substitutions, whereas K101E
(interface III) had a milder effect on binding (Fig. 3E). The
results from this binding assay, in conjunction with the structural
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Fig. 2. iASPP-regulated p53 target selectivity. (A) Intersection of DE genes identified by RNA-seq and genes with differential p53 binding identified by ChIP-
seq in iASPP-depleted cells. (B) FPKM values from RNA-seq analysis of different cellular conditions (Top) and University of California Santa Cruz (UCSC)
Genome Browser views of p53 occupancy from ChIP-seq (Bottom) for representative p53 targets from the above-mentioned targets coregulated by iASPP,
plusMDM2 as a well-known direct p53 target that did not show substantial coregulation by iASPP. Two batches of RNA-seq data (n = 2) were used. Error bars
denote SDs. RPM, reads per million; kb, kilobase. (C) Thirteen identified iPTGs, together with some representative p53 target genes (below the line), are listed
with their observed iASPP-regulated fold changes in RNA levels and p53 ChIP binding as well as identified p53 REs and major associated molecular functions.
The signature-corresponding C9 and G12 (highlighted in red) as well as the conserved C4, G7, C14, and C17 (highlighted in black) of a typical 20-bp unsplit
p53 consensus motif are indicated and deviations are in bold. (D) Luciferase reporter assay of transactivation of p53 response element in TIGAR by p53 with
cotransfection of iASPP in p53-null cancer cell lines H1299 and Saos-2. RLU, relative luminescence unit (fold changes relative to vector alone are indicated).
Three experiments were carried out in triplicate, and data from a representative set are shown. Error bars denote SDs. *P < 0.001 (2-tailed t tests). Samples
from the triplicates under the same condition were pooled together for Western blotting. Raw data for D are available from Mendeley Data at http://
dx.doi.org/10.17632/j75wt9b36n.1.
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analysis of the interfaces, led us to assign interface I as the major
p53–iASPP interface.
iASPP Displaces the Signature-Defining L1 Loop of p53. We next
analyzed the p53–iASPP crystal structure in the context of p53–
DNA interactions. Each p53 DBD monomer determines the
pentameric consensus DNA duplex motif in the RE, PuPuPuC(A/T)
(also called a quarter site). A corresponding middle quarter site
from the iASPP-regulated p53 consensus motif determined from
our sequence analysis is shown in Fig. 4 A, Inset. A p53 DBD
monomer interacts with this DNA duplex primarily via direct,
base-specific major-groove interactions involving the LSH motif.
In virtually all p53–DNA structures, R280 from the H2 helix an-
chors p53 to the cognate DNA duplex through 2 conserved hy-
drogen bonds to the invariant G on the pyrimidine-rich strand
(Fig. 4A). In comparison, K120 from the L1 loop prefers a G at
the second position of the pentamer (Fig. 4A).
We superimposed our iASPP–p53 complex on the classical
DNA complex using p53 as the reference (Fig. 4B). Overall,
iASPP engages p53 on the edge of the DNA-binding site, and
does not seem to clash directly with p53-bound DNA (Fig. 4 B
and C). However, the p53 L1 loop is displaced by iASPP such
that K120 at its tip is no longer able to make contacts with the
base at the second position of a quarter site. The prevalence of a
G at this position of a quarter site (G12 as illustrated in Fig. 4 A–C)
corresponds to the sequence signature we identified in iASPP-
regulated p53 REs.
In contrast to the displaced L1 loop, the other p53 DNA-
binding modules remain well suited to interact with DNA in the
iASPP complex. For instance, the H2 helix from the LSH motif
and the L3 loop retain essentially the same structures and sur-
face availability in the iASPP complex compared to the DNA-
binding structure (Fig. 4 B and C). In addition, we inspected the
surface charge of the p53–iASPP complex along the putative
DNA-binding groove (SI Appendix, Fig. S7A). Although iASPP
exhibits a generally negatively charged exterior, the p53–iASPP
complex retains a continuous, positively charged surface for
binding DNA (SI Appendix, Fig. S7A).
iASPP–p53–DNA Assembly Supports the Signature Symmetry. Typi-
cally, p53 is held together as a tetramer by its oligomerization
domain and recognizes its cognate DNA sequences through its
DBD. The consensus motif of p53 REs has a striking symmetry that
reflects the dimer-of-dimers architecture of p53 DBDs assembled
CTDODDBDPRDTAD 3931p53
Fr
eq
ue
nc
y 
(%
)
2
4
6
8
R175
G245
R248
R249
R273
R282
DBDPRDp53crys 62 292L1 H2
8281iASPP AR I AR II AR III AR IV SH3
AR I AR II AR III AR IV SH3 828625iASPPcrys
iASPP ARs
iASPP SH3
p53 DBD
iASPP tail N
C
N
AR II
AR III
AR IV
SH3
H2
Zn
L1
R175
G245
R248
R249 R273
R282
90°
p53 L1 (iASPP)
p53 L1 (2XWR)
H2
AR II H2
AR III H2
H1
AR II
H1
AR III
Varied Conserved−3 k T/eb c 3 k T/eb c
H115
R282
loop-sheet-helix
ARs
SH3
tail
F818
iASPPp53
I II III
W
ild
-ty
pe
(−A
SP
P)
R
26
7A
K1
01
A
N
28
8A
R
28
0A
R
24
8A
S1
21
A
R
28
2A
H
11
5A
W
ild
-ty
pe
Ve
ct
o
r
p53 mutations on interfaces with iASPP
In
pu
t
Pu
ll-
do
wn
I III
K1
01
E
R
28
2E
H
11
5E
W
ild
-ty
pe
Ve
ct
o
r
p53
iASPP
p53
iASPP
A
B C
D E
Fig. 3. Crystal structure of the p53–iASPP complex. (A) Schematic domain structures of human p53 (Left) and iASPP (Right). The codon distribution of somatic
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hotspots are in red. Domains are colored as in A. (C) Electron density (2FO − FC map as blue mesh) at p53–iASPP interface I, contoured at 1.0 σ. An apo p53 DBD
structure (orange) with an extended N terminus (PDB entry 2XWR chain B; the search model for molecular replacement) is superposed onto the iASPP-bound
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Solvent-accessible p53 and iASPP surfaces are colored by electrostatic potential (Middle) and residue conservation (Right) with interface residues outlined in
green. (E) Binding assay using His-tagged iASPPcrys to pull down full-length p53 and p53 mutants harboring single-point mutations targeting the interfaces
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on cognate DNA sequences, even in the absence of its oligomeri-
zation domain (Fig. 5A) (22).
When a single p53–iASPP complex is docked onto tetrameric
p53–DNA complexes, iASPP does not appear to overlap with any
of the symmetry-related p53 DBD molecules (Fig. 5B and SI Ap-
pendix, Fig. S8 A and B). Superposition of 4 iASPP complexes onto
the DNA complexes of p53, on the other hand, would introduce
minor clashes between the ankyrin-repeat domains of the adjacent
iASPP structures related by the translational symmetry (SI Appen-
dix, Figs. S7B and S8C), although it is possible that a slight archi-
tectural adaptation could accommodate a 4:4 iASPP–p53 assembly
on an unsplit p53 consensus sequence. Notably, there is no clash
between rotational symmetry-related iASPP structures (SI Appen-
dix, Figs. S7B and S8C).
We further noted the structural variations of the L1 loops
between the middle and the flanking p53 monomers in the tet-
rameric p53 assembly on a full consensus site (22, 23) or on the
prototypic CDKN1A RE (25). K120 at the tip of L1 from each
middle p53 DBD is well defined in the major groove to contact
DNA but outer L1 loops either become partially disordered (22)
or adopt a recessed conformation without direct DNA contacts
(23, 25).
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Fig. 4. iASPP displaces the L1 loop of p53. (A) p53 (cartoon)–DNA (sticks)
complex (PDB entry 1TUP; p53 as chain B). The principal DNA-contacting
modules of p53 (L1, L3, and H2) are in orange. The side chains of base-
recognizing K120 and R280 are illustrated as sticks showing hydrogen
bonds with DNA (donor–acceptor distance closer than 3 Å) indicated as
dashed lines. A typical pentameric quarter site on the purine-rich strand is
highlighted in color. Inset, a middle quarter site (positions 11 to 15) from the
iASPP-regulated p53 consensus motif. (B and C) Our iASPP complex super-
posed onto the classical DNA complex (PDB entry 1TUP) based on p53. iASPP
is represented as a cartoon in B and solvent-accessible surface in C. p53
L1 displacement by iASPP is indicated with an arrow. Orange, in complex
with DNA; cyan, with iASPP bound.
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Fig. 5. Model of the iASPP–p53–DNA assembly. (A) Full consensus site (or-
ange cartoon)-bound tetrameric p53 DBD (surface representation) assembly
(PDB entry 3KMD). The middle quarter site-binding p53 DBD monomers are
in gray and the outer quarter site-interacting monomers are in white. (B) The
iASPP complex superposed on the DNA–tetrameric p53 complex based on
the superposition of the p53 DBD (1 of the middle p53 DBDs as the refer-
ence). (C) Model of 2 iASPP molecules docked onto the middle 2 p53 DBD
monomers in the DNA–tetrameric p53 complex.
Chen et al. PNAS | August 27, 2019 | vol. 116 | no. 35 | 17475
M
ED
IC
A
L
SC
IE
N
CE
S
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ity
 o
f B
irm
in
gh
am
 (B
arn
es
 Li
bra
ry)
 on
 Fe
bru
ary
 18
, 2
02
0 
These structural observations suggest a functioning model of
2 centrally located iASPP molecules on tetrameric p53–DNA
complexes (Fig. 5C and SI Appendix, Fig. S8D) in concordance
with the iASPP-regulated p53 RE sequence signatures (C9 [G on
the opposite strand] and G12) being symmetrically positioned in
the middle p53 quarter sites.
Distinct p53–ASPP Architectures. Due to the sequence and struc-
tural homologies between the C-terminal regions of iASPP and
ASPP2 (sequence identity of 54.4% and RMSD of 1.24 Å for 190
Cα pairs), we originally anticipated p53–iASPP interactions to be
similar to those described for p53–ASPP2 (34). However, the p53–
iASPP structure is distinct from the published p53–ASPP2 complex.
ASPP2 binds to p53 DBD at a surface composed predominantly of
the L2 and L3 loops, on roughly the opposite side to iASPP (Fig. 6A).
The superposition of the p53–ASPP2 complex onto a p53–DNA
complex shows a major steric clash between the SH3 domain of
ASPP2 and the p53-bound DNA (Fig. 6A). A substantial steric
clash is also observed between the ankyrin repeats of ASPP2 and
the rotational symmetry-related p53 DBD monomer required for
DNA recognition (Fig. 6A).
The area of the interfaces between iASPP and ASPP2 with
p53 are similar (∼1,250 Å2 vs. ∼1,500 Å2, respectively), in line
with the comparable p53-binding affinities reported for iASPP
and ASPP2 (35). Nevertheless, ASPP2 and iASPP use distinct
residues for interaction with p53 (SI Appendix, Fig. S4B). A close
inspection of the p53-contacting residues in iASPP and ASPP2
shows clear differences at the interfaces. At the p53–ASPP2-
binding site involving the p53 L2 loop and ASPP2 ankyrin re-
peat IV (Fig. 6B), the bulky side chains of ASPP2 residues
(M1021, Y1023, and M1026) that contribute to van der Waals
interaction with p53 are divergent in iASPP (replaced by T722,
L724, and G727, respectively). In the ASPP2 SH3 domain,
L1113 enables optimized binding to p53 but is substituted with a
tyrosine residue common for SH3 domains in iASPP (Y814) (34,
36). On the other hand, at interface I of our p53–iASPP complex,
the charge complementarity between p53 and iASPP is predicted
to be disrupted by the equivalent, positively charged surface on
ASPP2 (Fig. 6C).
To further examine the differences in the binding of iASPP
and ASPP2 to p53, we compared the binding of each to p53 with
hotspot mutations found in cancer (Fig. 6D). Notably, binding of
iASPP to p53 was enhanced by the mutations R175H, G245D,
R249S, and R282W (Fig. 6D). This is intriguing given that, apart
from R282, these residues are not at the iASPP–p53 interface.
These mutations have been thought to destabilize p53 DBD
structure thereby disrupting its function (19). It has been
reported that p53 R282W, in the presence of stabilizing DBD
mutations, retains the overall wild-type fold, yet has a disordered
L1 loop in a crystal structure (residues 117 to 121) (53). This
corresponds to the region that changes conformation upon
iASPP binding (Figs. 3C and 4 B and C), rendering the iASPP-
binding surfaces more readily accessible. The other mutations
that affect p53 DBD conformation (except for G245S which
showed more restricted conformational changes in the L3 loop)
(53) likely also induce a more open structure in the DBD, par-
ticularly in the LSH motif where topologically the N- and C-
termini of wild-type p53 DBD meet. Conversely, frequent
p53 mutants R248Q, R273C, and R273H, which are believed to
largely retain the wild-type DBD fold but are defective in DNA
binding (19), bound iASPP similarly to the wild-type tumor
suppressor (Fig. 6D).
In contrast to the results for iASPP, p53 mutations R248Q and
G245S decreased ASPP2–p53 binding, whereas R282W did not
substantially affect the interaction (Fig. 6D). This is consistent
with a previous study looking at the binding between p53 DBD
and C-terminal ASPP2 (54). These findings support the model
that iASPP and ASPP2 have fundamentally different interactions
with p53, and that binding of iASPP is strengthened by mutations
that favor a more open structure in the DBD.
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Fig. 6. Distinct p53–ASPP architectures. (A) iASPP and ASPP2 (ARs in green
and SH3 in forest green; PDB entry 1YCS) p53 complexes superposed on the
same p53 DBD monomer in a DNA–tetrameric p53 structure (PDB entry
3KMD). (B) iASPP as in our p53 complex is superposed onto ASPP2 in its
p53 complex. ASPP2–p53 interface residues near the p53 (cyan) Zn (yellow
sphere)-binding site are indicated with ASPP2-equivalent iASPP residues il-
lustrated. A structure-based sequence alignment of the ASPP residues is
shown (Top). (C) ASPP2 colored by electrostatic potential (from a perspective
corresponding to iASPP illustrated on the Left). A superposition of iASPP and
ASPP2 (as in their p53 complexes) is shown (Right). (D) Pull-down assays
between full-length p53 (cancer-derived and iASPP-interface mutants) and
iASPPcrys or ASPP2crys. Fig. 3E is shown here again for comparisons. Raw
data for D are available from Mendeley Data at http://dx.doi.org/10.17632/
j75wt9b36n.1.
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iASPP and HPV E6 Interactions Highlight a Functional p53 Interface.
The p53 DBD is not only responsible for sequence-specific in-
teraction with cognate DNA, but is also associated with cellular
proteins and targeted by viral oncoproteins. Previously all endoge-
nous partners structurally characterized as p53 DBD complexes,
including ASPP2 (34), 53BP1 (55), and BCL-xL (56), cluster at the
p53 DNA-binding surface where SV40 LTag interaction maps (57)
(Fig. 7A). A recent crystal structure determination showed that the
HPV oncoprotein E6, in complex with an E6-associated protein
(E6AP) peptide, interacts with the N-terminal arm and the LSH
motif of p53 DBD (58). This HPV E6-binding site substantially
overlaps where iASPP binds in our p53–iASPP structure, and there
is considerable steric hindrance between iASPP and E6AP-bound
E6 when the complexes are superimposed, based on p53 (Fig. 7A).
Our structural analysis led us to hypothesize that iASPP may com-
pete with E6 to stabilize p53.
Consistent with these structural observations, in a classical
HPV E6-mediated p53 degradation assay, iASPP inhibited
p53 degradation induced by the HPV-16 E6 oncoprotein in a
dose-dependent manner (Fig. 7B). In comparison, purified C-
terminal ASPP2 only mildly reduced the degradation of p53 at
the highest concentrations administrated (Fig. 7B). We further
tested single-point mutations of solvent-exposed residues at rele-
vant p53 surfaces and found that the iASPP binding-defective p53
H115A and H115E mutants were as susceptible to HPV-16 E6-
mediated degradation as the wild type but the degradation could
no longer be efficiently blocked by iASPP (Fig. 7C). In line with a
previous report (58), the alanine substitutions of p53 residues
K101 and H115, which mediate p53–HPV-16 E6 interaction, do
not substantially affect p53 degradation induced by HPV-16 E6.
However, p53 K101E and H115R mutants are resistant to HPV-
16 E6-mediated degradation (Fig. 7C).
Notwithstanding their overlapping binding surfaces on p53
DBD, iASPP and HPV E6 adopt distinct molecular mechanisms
to inhibit p53 activities. Our p53–iASPP complex reveals that
iASPP packs against the H2 helix of p53 DBD and displaces p53
L1 loop from its DNA-binding position, reminiscent of a recessed
L1 conformation (25) (Fig. 7D), but does not impact DNA binding
by other p53 DNA-recognizing modules, which we deem re-
sponsible for specific, iASPP-regulated changes in the p53 RE
motif characterized in our genomic analysis. These observations
are in line with a biological role of iASPP in fine-tuning p53 ge-
nomic binding and transcriptional output as a means of p53 reg-
ulation. On the other hand, high-risk type HPV E6 binding does not
sterically interfere with DNA interaction or introduce any appre-
ciable structural changes to p53 DNA-binding modules. The L1 loop
of p53 in complex with E6 aligns well with apo and DNA-binding
L1 structures and is favorably positioned to interact with DNA. In
fact, the p53 L1 appears somewhat restricted in this position as a
result of E6 interaction. Instead of steric hindrance or allosteric
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Fig. 7. Analysis of p53 DBD complexes. (A) Complexes of p53 with iASPP (magenta surface representation) and ASPP2 (green) are superposed on the classical DNA–
p53 complex, using p53 DBD (white) as the reference (Left). Complexes with viral oncoproteins HPV-16 E6 (E6AP-bound; E6, yellow cartoon; E6AP, black ribbon) and
SV40 LTag (pink) were similarly superimposed based on p53 (Middle). Other p53 DBD complexes, with 53BP1 (red cartoon) and BCL-xL (blue cartoon) are compared by
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regulation, HPV E6 recruits E6AP to ubiquitinate p53 and in turn
mediate p53 degradation, thereby attaining a more thorough in-
hibition for viral reproduction. Thus, although iASPP and E6 share
an interaction surface, iASPP has a unique mode of p53 regulation.
Discussion
Our structure of the p53 DBD in complex with iASPP exemplifies
a mechanism through which direct interactions with partner pro-
teins impart DNA-binding refinement and target gene selectivity
to transcription factors. The accomplishment of binding affinity
and sequence specificity across a genome entails multiple DNA-
interacting structural modules of a TF. In relation to protein–
DNA interactions, p53 resembles most gene regulatory proteins in
that it uses an α-helix (the C-terminal H2 in the DBD) to contact
the major groove of cognate DNA (19). In conjunction with the
L3 loop, H2 interactions define p53 binding to the conserved core
of its cognate DNA half site. Notably, the L1 loop of p53 packing
against H2 makes further, sequence-specific interactions with
more variable bases flanking the core motif in the major groove,
corresponding to the sequence signatures enriched in iASPP-
regulated p53 response elements. A similar helix–loop arrange-
ment has been described for the GATA-1–DNA complex (59). Our
genomic and structural analyses advocate that iASPP achieves dif-
ferential p53 inhibition by modulating the peripheral contacts made
by p53 L1 without disrupting the anchoring p53–RE interactions
mediated by its H2 and L3 modules. TF regulatory proteins could act
similarly to iASPP to modulate TF target selectivity. Furthermore,
the displacement of p53 L1 by iASPP could potentially affect p53–
Tip60 interactions and Tip60-mediated acetylation of L1 residue
K120. Since K120 acetylation is critical for p53-dependent apoptosis
but dispensable for growth arrest (5), this mechanism could con-
tribute to the modulation of p53 target gene selectivity by iASPP.
Beyond the modulation of p53–DNA interactions, iASPP binding
might influence p53 interactions with the general transcriptional
machinery, for example the RPB1 and RPB2 subunits (60) of the
RNA polymerase II, which could contribute to the differential
p53 regulation by iASPP observed in our genomic analysis.
Our genome-wide surveys provide a more complete landscape of
iASPP-mediated p53 regulation. We identified iPTGs previously
not associated with iASPP, for instance TIGAR, an antiapoptosis
and prosurvival gene, involved in metabolism and ROS control. The
majority of the identified iPTGs participate in p53-mediated cellular
life-or-death decisions, in line with an apoptosis-related function of
iASPP. Of note, several iPTGs, such as ACTA2, FHL2, PARD6B,
and SLC30A1, may be linked to iASPP-related phenotypes such as
sudden cardiac death and dilated cardiomyopathy (61, 62).
The distinct p53 interfaces of the ASPP family members,
iASPP and ASPP2, are unexpected and the observed differential
interactions offer a fresh perspective on the mechanisms gov-
erning the opposing biological functions of the ASPP molecules
in regulating p53 and its family members p63 and p73 in devel-
opment, tissue homeostasis, and cancer. In accord with the
ASPP2–p53 structural study (34), the C-terminal region of
ASPP2 competes with DNA for p53 binding in an in vitro assay
(54) and inhibits p53 transcriptional activity in cells (31). Full-
length ASPP2, on the other hand, is able to stimulate the target
selective transcriptional activity of p53 on genes such as BAX
(31), indicating this stimulatory activity of ASPP2 requires the
rest of the protein. It remains obscure how full-length ASPP2 se-
lectively stimulates the transcriptional activities of p53. In light of
the p53–iASPP structure shown here, it is possible that full-length
ASPP2 may compete with iASPP to bind p53 via a similar L1 loop-
containing interface and/or to form ASPP2–p53–DNA ternary
complexes in cells to stimulate p53 target-selective transcription.
Interestingly, previous nuclear magnetic resonance (NMR) char-
acterization of p53–ASPP2 interactions in solution showed that the
binding of C-terminal ASPP2 induces structural changes in L1 and
H2 of p53 in addition to the binding surface described in the early
crystal structure (34, 54), suggesting the possibility that our observed
p53–iASPP interface is also relevant to p53–ASPP2 interactions as a
secondary binding site. Furthermore, the linker between p53 DBD
and OD was shown to contribute to binding the iASPP SH3 domain
(37), which is available for interaction in our p53 DBD complex.
These discrete p53–iASPP interactions may combine to provide
affinity and specificity required for iASPP-mediated p53 regulation.
Mapping cancer-derived iASPP mutations in relation to our
crystal structure of the p53 complex did not show a clear pattern
(SI Appendix, Fig. S7C). Indeed, there is growing evidence that
overexpression, rather than mutation, of iASPP conveys its on-
cogenic properties. In addition to our previous characterization
in p53 wild-type breast cancer (32), elevated iASPP levels have
recently been reported in multiple human cancers, including
bladder cancer (63), non-small-cell lung cancer (64), ovarian clear
cell carcinoma (65), colorectal cancer (66), and particularly in
acute leukemia where p53 mutations are relatively rare (67, 68).
A crucial advance from this study is the identification of a second
molecular interaction surface on p53 DBD that holds promise for
targeted cancer therapies. ASPP2 and iASPP mirror the p53
interactions of 2 of the best-characterized p53-hijacking viral
oncoproteins, SV40 LTag and HPV E6, respectively. The
ASPP2 and SV40 LTag-binding site, involving the L3 loop of
p53, represents a classic p53 interaction hub that contacts both
DNA and other proteins such as 53BP1 and BCL-xL. This
p53 surface is also where most cancer-derived mutations map
and 5 out of 6 p53 mutational hotspots locate here. However, it
presents a formidable challenge for therapeutic targeting be-
cause this surface is required for DNA interaction. On the other
hand, the iASPP site, which is targeted by HPV E6, does not
directly engage DNA. Hotspot R282 stabilizes p53 L1 at this
surface (53), and our finding of increased iASPP binding to
tumor-derived p53 R282W could contribute to the oncogenic
properties of this mutation. The intrinsic flexibility of iASPP-
interacting L1 could be modulated by engineered mutations
(69), and has been proposed for reactivation of p53 mutants (70).
In agreement with this hypothesis, an ASPP2-derived peptide
that binds L1 and H2 of p53, has been shown previously to
stabilize mutant forms of p53 and rescue p53 functions in cells
(71, 72). Our results in conjunction with previous studies provide a
structural and functional framework for designing p53-targeting
anticancer agents to achieve dissociation of oncoproteins inhibit-
ing wild-type p53 as well as rescue of p53 mutations.
Materials and Methods
HCT116cellswere treatedwith siRNAmolecules (Dharmacon)andused toperform
the RNA-seq and the ChIP-seq (p53 antibody FL-393, Santa Cruz Biotechnology sc-
6243) experiments. The sequencing data were analyzed with standard bio-
informatics pipelines. p53crys (humanp53 [UniProt accession codeP04637] residues
62 to 292) and iASPPcrys (human iASPP [UniProt Q8WUF5] residues 625 to 828)
were expressed in Escherichia coli and purified to homogeneity. The p53–iASPP
complex was prepared as an equimolar mixture of the purified proteins before
size exclusion chromatography. The peak fractions were combined and concen-
trated for crystallization trials. Diffraction-quality crystals were optimized
in 18% (wt/vol) polyethylene glycol 3350, 0.18 M trisodium citrate. Crys-
tallographic data were collected and processed, and the structure was
determined and analyzed, essentially as described previously (73). A de-
tailed description of the materials and methods used in this study is pro-
vided in SI Appendix, Supplementary Materials and Methods. Raw data
files as noted in the legends of Figs. 2, 3, and 6 are available from Mendeley
Data at http://dx.doi.org/10.17632/j75wt9b36n.1.
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